T John Winhusen

University of Cincinnati

NIH Rank #9297
  • Early Career

NIH Funding · FY2024

Total Funding
$1.4M
Fiscal year 2024
Grants Awarded
4
Active NIH grants
National Rank
#9,297
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $1.4M across 4 grants · National rank #9297.

Top grants by award amount

T John Winhusen's NIH grant portfolio, ranked by award amount.

  • 3UG1DA013732-25S2UG1
    CTN - Effects of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro and Zepbound) on incidence and outcomes of stimulant use disorders and opioid use disorder in real-world populations: target tr
    $502.7K
    award amount
  • 3UG1DA013732-25S1UG1
    CTN - Evaluation of SeMaglutide as an Adjunct to buprenorphine treatment for the treatment of opioid use disorder: A pragmatic Randomized placebo-controlled Trial (SMART)
    $498.5K
    award amount
  • 5UG1DA013732-25UG1
    The Ohio Valley Node of the Clinical Trials Network
    $284.9K
    award amount
  • 3UG1DA013732-24S1UG1
    IMPROVE
    $146.3K
    award amount

Affiliation

Institutions that have administered grants for T John Winhusen.

Affiliated with University of Cincinnati (OH).

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    University of Cincinnati
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #9297